

CIOMS WORKING GROUP XII Benefit-Risk Balance for Medicinal Products (Update of CIOMS IV)

Participants as at February 2020

Patrick **Caubel**, Pfizer

Guacira **Corrêa de Matos**, ANVISA, Brazil

Stephen J.W. **Evans**, London School of Hygiene & Tropical Medicine, UK

Scott **Evans**, Milken Institute School of Public Health, George Washington University, USA

Richard **Forshee**, FDA CBER, USA

Stewart **Geary**, Eisai

Sergei **Glagolev**, Roszdravnadzor, Russian Federation

Takahiro **Goto**, WHO

Sanna **Hill**, CIOMS

Vicky **Hogan**, Health Canada, Canada

Karen **Kaplan**,* MSD

Sara **Khosrovani**, Medicines Evaluation Board, Netherlands

Noriaki **Kitami**, PMDA, Japan

Leila **Lackey**, FDA CDER, USA

Hussein **Laljee**,* Gilead

Hervé **Le Louet**, CIOMS

Shahrul **Mt-Isa**, MSD

Leo **Plouffe**, Bayer

George **Quartey**, Roche

Lembit **Rägo**, CIOMS

Cheryl **Renz**, AbbVie

Tomas **Salmonson**, Former Chair CHMP

Stephanie **Storre**, Swissmedic

Sabine **Straus**, Medicines Evaluation Board, Netherlands

Stephanie **Tcherny-Lessenot**, Sanofi

Steffen **Thirstrup**, University of Copenhagen/Copenhagen Centre of Regulatory Science

Panos **Tsintis**, CIOMS

Mariko **Tsukuda**, PMDA, Japan

Sebastian **Vulcu**, Boehringer-Ingelheim

Julie **Williams**, Medicines and Healthcare Products Regulatory Agency, UK

Hong **Yang**,* FDA CBER, USA

Qun-Ying **Yue**, Uppsala Monitoring Centre, Sweden

Xi Sherry **Zhang**, Gilead

* Designates alternate members who will participate in Working Group meetings in case the member from the same institution cannot attend.